Overview

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborator:

Massachusetts General Hospital

Treatments:

Ergocalciferols